Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C27H34N4O10.ClH |
| Molecular Weight | 611.041 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC(=CC(OC)=C1OC)C(=O)OC(CN2CCOCC2)CN3N=NC4=C(C=C(OC)C(OC)=C4OC)C3=O
InChI
InChIKey=HFRYURAEFNEFQL-UHFFFAOYSA-N
InChI=1S/C27H34N4O10.ClH/c1-34-19-11-16(12-20(35-2)23(19)37-4)27(33)41-17(14-30-7-9-40-10-8-30)15-31-26(32)18-13-21(36-3)24(38-5)25(39-6)22(18)28-29-31;/h11-13,17H,7-10,14-15H2,1-6H3;1H
DescriptionCurator's Comment: Publication in URI also on PubMed, but title only: https://www.ncbi.nlm.nih.gov/pubmed/7196735
Curator's Comment: Publication in URI also on PubMed, but title only: https://www.ncbi.nlm.nih.gov/pubmed/7196735
Razinodil was developed as a coronary vasodilator, a drug that reduces blood pressure by dilating blood vessels. It was tested for its potential as a drug in ischemic myocardial diseases. In a canine heart-lung laboratory model, it increased coronary blood flow without increasing oxygen consumption. Only slight negative chronotropic (heart rate) and inotropic (cardiac contraction) effects were reported. Razinodil also improved the survival rate of miniature pigs after an induced heart attack.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
145K25F0S8
Created by
admin on Mon Mar 31 22:32:20 GMT 2025 , Edited by admin on Mon Mar 31 22:32:20 GMT 2025
|
PRIMARY | |||
|
169141
Created by
admin on Mon Mar 31 22:32:20 GMT 2025 , Edited by admin on Mon Mar 31 22:32:20 GMT 2025
|
PRIMARY | |||
|
DTXSID60952632
Created by
admin on Mon Mar 31 22:32:20 GMT 2025 , Edited by admin on Mon Mar 31 22:32:20 GMT 2025
|
PRIMARY | |||
|
30271-90-0
Created by
admin on Mon Mar 31 22:32:20 GMT 2025 , Edited by admin on Mon Mar 31 22:32:20 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
